SI21372A - Novi fibroblastni rastni faktorji - Google Patents

Novi fibroblastni rastni faktorji Download PDF

Info

Publication number
SI21372A
SI21372A SI200120066A SI200120066A SI21372A SI 21372 A SI21372 A SI 21372A SI 200120066 A SI200120066 A SI 200120066A SI 200120066 A SI200120066 A SI 200120066A SI 21372 A SI21372 A SI 21372A
Authority
SI
Slovenia
Prior art keywords
fgf
polypeptide
amino acid
nucleotide sequence
human
Prior art date
Application number
SI200120066A
Other languages
English (en)
Slovenian (sl)
Inventor
Peter W. Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SI21372A publication Critical patent/SI21372A/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200120066A 2000-12-08 2001-12-10 Novi fibroblastni rastni faktorji SI21372A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
SI21372A true SI21372A (sl) 2004-06-30

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200120066A SI21372A (sl) 2000-12-08 2001-12-10 Novi fibroblastni rastni faktorji

Country Status (21)

Country Link
US (2) US20020151496A1 (xx)
EP (1) EP1389237A2 (xx)
JP (1) JP2005506275A (xx)
KR (1) KR20040052442A (xx)
CN (1) CN1518597A (xx)
AU (1) AU2603402A (xx)
BG (1) BG107888A (xx)
BR (1) BR0116507A (xx)
CA (1) CA2431374A1 (xx)
CZ (1) CZ20031570A3 (xx)
EE (1) EE200300269A (xx)
HU (1) HUP0400657A1 (xx)
IL (1) IL156259A0 (xx)
MX (1) MXPA03005142A (xx)
NO (1) NO20032573L (xx)
PL (1) PL366158A1 (xx)
RU (1) RU2329058C2 (xx)
SI (1) SI21372A (xx)
SK (1) SK7012003A3 (xx)
WO (1) WO2002046424A2 (xx)
ZA (1) ZA200305236B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
EP1469880A4 (en) * 2002-01-15 2006-04-26 Lilly Co Eli METHOD FOR REDUCING MORBIDITY AND MORTALITY IN CRITELY SICK PATIENTS
CA2521217C (en) 2003-04-01 2013-05-14 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
EP3597666A3 (en) 2011-07-01 2020-04-22 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
KR20150104579A (ko) 2012-12-27 2015-09-15 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
SG11201606018UA (en) 2014-01-24 2016-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3924300A (en) * 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
ATE446365T1 (de) * 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic Menschliches fgf-21 gen und genexpressionsprodukte
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
CA2415123A1 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
SK7012003A3 (en) 2004-04-06
RU2003119657A (ru) 2005-02-27
IL156259A0 (en) 2004-01-04
US20020151496A1 (en) 2002-10-17
BG107888A (bg) 2004-08-31
NO20032573L (no) 2003-07-22
PL366158A1 (en) 2005-01-24
KR20040052442A (ko) 2004-06-23
WO2002046424A3 (en) 2003-11-27
EE200300269A (et) 2003-10-15
AU2002226034A2 (en) 2002-06-18
EP1389237A2 (en) 2004-02-18
CZ20031570A3 (cs) 2004-01-14
US20080057076A1 (en) 2008-03-06
NO20032573D0 (no) 2003-06-06
CA2431374A1 (en) 2002-06-13
MXPA03005142A (es) 2004-10-15
ZA200305236B (en) 2005-06-29
WO2002046424A2 (en) 2002-06-13
BR0116507A (pt) 2004-01-06
HUP0400657A1 (en) 2006-04-28
JP2005506275A (ja) 2005-03-03
AU2603402A (en) 2002-06-18
CN1518597A (zh) 2004-08-04
RU2329058C2 (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
US6004937A (en) Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US8986690B2 (en) Modulation of activity of neurotrophins
EP1071772A2 (en) Fizz proteins
CA2343927A1 (en) Artemin, a novel neurotrophic factor
US20160152677A1 (en) Single domain tdf-related compounds and analogs thereof
Heller et al. Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development
AU735794B2 (en) Don-1 gene and polypeptides and uses therefor
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
AU2002226034B2 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
AU2002226034A1 (en) Fibroblast growth factors
EP0934413A1 (en) Placental-derived prostate growth factors
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
Buj-Bello Neurotrophic actions of GDNF and neurturin in the developing avian nervous system and cloning and expression of their receptors
AU2016213791A1 (en) Single domain TDF-related compounds and analogs thereof

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20090717